Please use this identifier to cite or link to this item: http://repository.i3l.ac.id/jspui/handle/123456789/551
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAshiila, Putri-
dc.date.accessioned2022-09-26T07:10:42Z-
dc.date.available2022-09-26T07:10:42Z-
dc.date.issued2022-06-06-
dc.identifier.urihttp://repository.i3l.ac.id/jspui/handle/123456789/551-
dc.description.abstractNasopharyngeal carcinoma (NPC) is a rare malignancy. It is, however, endemic in the regions of Southeast Asia, and has a poor prognosis. In Indonesia, NPC is the fourth most common cancer of both sexes, yet little is recorded about it. NPC is related to Epstein-Barr virus (EBV) infection; this means that NPC is a potential target for immunotherapy strategies. Thus far, there has been much research for NPC vaccines targeting the viral genes of the EBV which are not expressed by cancer cells. Developing a multi epitope-based NPC vaccine might be helpful for patients with advanced cancer stages and who are resistant to treatment. Targeting the overexpressed antigens by the tumor may evoke immune response against the cancer cell. NPC has overexpressed levels of peptidyl-prolyl cis-trans isomerase (PIN1), which stimulates activating transcription factor 1 (ATF1) and tumorigenesis. Another overexpressed gene in NPC is ATP-binding cassette subfamily C member 5 (ABCC5). Its overexpression is reported in paclitaxel resistant NPC cells. A multi-epitope vaccination based on PIN1 and ABCC5 peptides was created in silico in this study. The ability of the proposed vaccination to elicit a successful immune response was evaluated with an in silico immunological simulation. In silico, the vaccine's overall quality was confirmed, and structural modeling proved the vaccine's stability. Docking tests demonstrated that the vaccine had steady interactions with Toll-Like Receptors. According to the computational assessments, the developed multiepitope vaccine is antigenic and immunogenic, and can trigger specific immune responses, making it a promising vaccination candidate against NPC.en_US
dc.language.isoenen_US
dc.publisherIndonesia International Institute for Life Sciencesen_US
dc.relation.ispartofseriesBM 22-015;T202206017-
dc.subjectB-cell epitopesen_US
dc.subjectT-cell epitopesen_US
dc.subjectPIN1en_US
dc.subjectABCC5en_US
dc.subjectvaccine designen_US
dc.subjectimmunoinformaticsen_US
dc.subjectNPCen_US
dc.titleImmunoinformatics Prediction of Cancer Antigen to Develop Multi-epitopes Cancer Vaccinesen_US
dc.typeThesisen_US
Appears in Collections:Biomedicine

Files in This Item:
File Description SizeFormat 
Chapter 1.pdfChapter 12.27 MBAdobe PDFView/Open
Cover.pdfCover2.4 MBAdobe PDFView/Open
References.pdfReferences2.27 MBAdobe PDFView/Open
Abstract.pdfAbstract2.27 MBAdobe PDFView/Open
BM 22-016 Putri Ashiila.pdf
  Restricted Access
Full text2.62 MBAdobe PDFView/Open Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.